Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: a review of FDA Adverse Events Reporting System data.

Godsfavour UmoruMatthew TaitanoSarah BeshayPolly NiravathAdriano R Tonelli

Published in: ERJ open research (2020)

This letter highlights a rare association of anti-HER2 cancer therapy with development of pulmonary arterial hypertension, based on a review of data from the FDA https://bit.ly/2X90xDu.

Keyphrases

pulmonary arterial hypertension
pulmonary artery
pulmonary hypertension
cancer therapy
electronic health record
drug delivery
adverse drug
emergency department
coronary artery
deep learning